Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-FR Version v8-FR
Language French French
Date Updated 2019-04-10 2019-03-13
Drug Identification Number 02324571 02324571
Brand name SANDOZ RIVASTIGMINE SANDOZ RIVASTIGMINE
Common or Proper name RIVASTIGMINE RIVASTIGMINE
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients RIVASTIGMINE RIVASTIGMINE
Strength(s) 3MG 3MG
Dosage form(s) CAPSULE CAPSULE
Route of administration ORAL ORAL
Packaging size 4X14/bl 4X14/bl
ATC code N06DA N06DA
ATC description ANTI-DEMENTIA DRUGS ANTI-DEMENTIA DRUGS
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date
Actual start date 2019-01-23 2019-01-23
Estimated end date 2019-03-18 2019-03-18
Actual end date 2019-03-22
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments